Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

Propranolol 8Timolol 5Prednisolone 4Prednisone 3Adrenergic beta-Antagonists 3Solutions 2Saline Solution 2Methylprednisolone 2Adrenal Cortex Hormones 2prednisolone phosphate 1Vincristine 1Tomography, Optical Coherence 1Steroids 1Sodium Chloride 1Sirolimus 1Population Groups 1Ointments 1Nadolol 1Mupirocin 1Leuprolide 1Lasers, Semiconductor 1Lasers, Dye 1Imiquimod 1Gels 1Everolimus 1Bleomycin 1Atenolol 1Acebutolol 168Ga-1,4,7-triazacyclononane-N,N',N''-triacetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hemangioma × Sirolimus × Clear all
NCT04077515 2023-01-30

Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

Children's Hospital of Fudan University

Phase 4 Completed
92 enrolled

Kaposiform Hemangioendothelioma, Hemangioma, Kasabach-Merritt Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡